Moderna's personalized mRNA cancer vaccine hits Phase 3 success: 34 neoantigens, 42 days
a16z · youtube · 2026-09-02
In an a16z podcast, Moderna CEO Stéphane Bancel details the positive Phase 3 results for its personalized melanoma mRNA vaccine with Merck. The treatment sequences a patient's tumor, algorithmically picks up to 34 key neoantigens, and encodes them into a patient-specific mRNA, delivered in 42 days from biopsy. They also cover manufacturing at scale, regulation of per-patient medicines, and pipelines in lung, kidney, bladder, pancreatic and gastric cancers, plus rare genetic and autoimmune diseases.
More from Research
- HydroGym RL platform for fluid dynamics published in Nature with 60+ environments — ricardovinuesa · 2026-09-03
- Paper proposes agents that outlive their model, harness, and host by splitting identity from plumbing — omarsar0 · 2026-09-03
- Stanford paper: steering directions causally shift context-vs-memory choice, but barely transfer across tasks — niloofar_mire · 2026-09-03
- Meta's Muse Spark jumps 1.1 to 1.3 in 55 days, photo-to-3D simulation at $0.60 — alexandr_wang · 2026-09-03
- Developer once tried building AI benchmark from Puzzlescript, similar to ARC-AGI-3 — Darpinian · 2026-09-03
- Do induction heads and attention sinks count? Debate over interpretability's missed milestone — aryaman2020 · 2026-09-03